Actinogen Medical Limited announces that the first patient has been randomized and treated in the XanaMIA phase 2b clinical trial in patients with biomarker-positive mild to moderate Alzheimer's disease. This represents the culmination of the site and screening setup phase of the trial when patient pre-screening for elevated levels of the pTau blood biomarker commenced at multiple clinical sites. The XanaMIA trial is a double-blind placebo-controlled randomized trial design whic

Read more...

Pulmocide Ltd., a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announced topline results from the OPERA-S study: a Phase 2 safety and tolerability study in lung transplant patients receiving inhaled opelconazole monotherapy as prophylaxis against pulmonary aspergillosis. Opelconazole is an investigational inhaled triazole antifungal being developed to prevent and treat pulmonary asperg

Read more...

Enliven Therapeutics, Inc., a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced positive proof of concept data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) who are relapsed, refractory, or intolerant to available tyrosine kinase inhibitors (TKIs) (NCT05304377). ELVN-001 is a potent, highly selective, potentially best-in-class sm

Read more...

ViGeneron GmbH, a next-generation clinical-stage gene therapy company, today announced that the first patient has been dosed in its Phase Ib clinical trial evaluating intravitreal injection of VG901 to treat retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene. This milestone marks an important advance as the company continues to leverage its next-generation technology platforms to develop groundbreaking gene therapies addressing critical unmet medical needs. “By de

Read more...

The life science group Sartorius and U.S.-based startup TheWell Bioscience have agreed to partner on the further development of hydrogels and bioinks tailored to produce 3D advanced cell models for drug discovery workflows. In addition to this, Sartorius will expand the portfolio of its lab division by distributing TheWell Bioscience's products and invest in a minority shareholding in the company. TheWell Bioscience is a pioneer in the field of animal-free hydrogels and bioinks,

Read more...

Osteolabs GmbH, an innovative diagnostic company applying its proprietary CIM (Calcium isotope marker) technology for the early detection of Calcium-related metabolic bone diseases affecting over 1 billion patients worldwide, announced today an oral and poster presentation at the world´s leading clinical conference on bone, joint and muscle health (WCO-IOF-ESCEO) taking place in London from April 11-14, 2024 highlighting new clinical data from over 2.400 OsteoTest routine samples.

Read more...

Today Toxys announces the peer-reviewed publication of the positive results from an international interlaboratory validation of ToxTracker©. ToxTracker is an in vitro method that accurately predicts genotoxicity without the use of animals. The results constitute an essential part of the approval process by the OECD for international acceptance of novel methods by regulatory authorities. The evaluation was finalized earlier in the year and data have been submitted to the OECD showing that

Read more...

Celonic has signed a commercial license agreement with Revvity for its CHOSOURCE™ expression platform and TnT transposon technology. The Revvity expression platform will be used in combination with Celonic’s expertise and workflows to enhance the cell line development of monoclonal antibodies (mAbs) and complex proteins.   GS-CHOvolution® is based on Revvity’s gene-edited Glutamine Synthetase (“GS”) knockout Chinese Hamster Ovary (CHO-K1) cGMP-

Read more...